Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

Background: Pediatric patients with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive acute lymphoblastic leukemia (ALL) are currently treated with the tyrosine kinase inhibitor (TKI) imatinib added to a chemotherapy backbone that also contains several courses of high-dose methotre...

Descripción completa

Detalles Bibliográficos

Autores principales:	Inge M. van der Sluis, Nikita D. van Dijk, Leiah J. Brigitha, Freya M. Steinhauer, Rob Pieters
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2023-12-01
Colección:	EJC Paediatric Oncology
Materias:	Acute lymphoblastic leukemia Imatinib High-dose methotrexate Clearance Pediatric
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2772610X23001113
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!